Biotech Values

[dewophile]

This is probably not new but Luly highlighted the fact that royalties from the PI in the first gen regimen is predicated on sales allocated to the PI specifically, and not the regimen as a whole. So the fact more sales are proportionally going to be on a 2 drug regimen for example as japan ramps up will help them get to higher royalty tiers faster (in addition to calculations based on 45% of sales for 2 drug vs 3 drug regimen like vpak)